Clinical features and survival analysis in acute myeloid leukemia patients with SRSF2 gene mutation
Objective:To investigate the clinical characteristics and the efficacy of allogeneic hematopoietic stem cell transplantation(allo-HSCT)in acute myeloid leukemia(AML)patients with SRSF2 gene mutation.Methods:From June 2016 to December 2022,the clinical data of patients admitted to the First Affiliated Hospital of Soochow University with SRSF2 mutations detected by next-generation sequencing were retrospectively ana-lyzed.Results:57 patients with AML were included in the study,comprising 42 males(73.7％)and 15 females(26.3％),with a median age of 60(17-83)years.Among the 57 patients with SRSF2 mutations,18 cases(31.6％)had SRSF2 P95H mutations,15 cases(26.3％)had SRSF2 P95L mutations,and 8 cases(14.0％)had SRSF2 P95R mutations.SRSF2 P95H mutations are associated with older age,increased white blood cell count,and higher VAF values.Co-mutation gene analysis showed that the most common concomitant gene muta-tion in SRSF2-mutated AML patients was the RUNX1 mutation(33.0％).Survival analysis showed that the 2-year overall survival(OS)and 2-year disease-free survival(DFS)of 57 cases SRSF2-mutated AML patients were 29.6％and 24.7％,respectively.The 2-year OS and DFS were 46.9％and 41.0％in the allo-HSCT group and 20.4％and 11.7％in the chemotherapy group,respectively.The two groups had significant differences in OS(P=0.012 4)and DFS(P=0.013 3).The results of multivariate analysis showed that age was an independent risk factor for OS(HR=2.385,95％CI 1.074-5.298,P=0.033)and DFS(HR=3.378,95％CI 1.223-9.334,P=0.019)in SRSF2-mutated AML patients.Conclusion:Allo-HSCT can improve the prognosis of AML patients with SRSF2 gene mutation.In addition,age can be an independent risk factor for OS and DFS in AML patients with SRSF2 mutations.
万方数据
维普
